TriSalus Life Sciences Announces Late Breaker and Additional Data Presentations on Liver Metastases and Pancreatic Cancer at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

TriSalus Life Sciences® Inc., , an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced...

Related Keywords

California ,United States ,Texas ,San Diego ,Chandrac Ghosh ,Sapanp Patel ,Michaels Lee , ,Twitter ,University Of Texas Md Anderson Cancer Center ,Nasdaq ,Trisalus Life Sciences ,Linkedin ,Uveal Melanoma Program ,Society For Immunotherapy Of Cancer ,Exchange Commission ,Trisalus Life ,Annual Meeting ,Breaker Oral Presentation ,Clinical Activity ,Immune Checkpoint Inhibition ,Metastatic Uveal Melanoma Liver Metastasis ,Late Breaking Abstract Session ,Poster Hall ,Pressure Enabled Intrapancreatic Delivery ,Checkpoint Blockade ,Locally Advanced Pancreatic Adenocarcinoma ,Initial Safety ,Feasibility Experience ,Associate Professor ,Subcutaneously Enhances ,Anti Tumor Immunity ,Pressure Enabled Drug Delivery ,Treating Liver Metastasis ,Infusion System ,Pancreatic Retrograde Venous Infusion System ,Pressure Enabled Regional Immuno Oncology ,Private Securities Litigation Reform Act ,Markets ,